REFERENCES
- Johannessen SI, Battino D, Berry D, Bialer M, Kramer G, Tomson T, Patsalos P. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25(3)347–363, [PUBMED], [INFOTRIEVE], [CSA]
- Lee C, Nechyba C, Gunn V. Drug doses. The Harriet Lane Handbook: A Manual for Pediatric House Officers16th, Johns Hopkins. Mosby, Philadelphia 2002; 869
- Traub SJ, Howland MA, Hoffman RS, Nelson LS. Acute topiramate toxicity. J Clin Toxicol 2003; 41(7)987–990, [CSA], [CROSSREF]
- May TW, Rambeck B, Uwe J. Serum concentration of topimarate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 2002; 24(3)366–374, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Penovich PE, Schroeder M, Gates JR, et al. Clinical experience with topiramate: correlation of serum levels with efficacy and adverse effects. Epilepsia 1997; 38(8)181, [CSA]
- Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blinded, randomized trial of topimarate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52(7)1338–1344, [PUBMED], [INFOTRIEVE], [CSA]
- Contin M, Riva R, Albani F, et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2002; 23: 332–337, [CSA], [CROSSREF]
- Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blinded, randomized trial of topimarate in Lennox-Gestaut Syndrome. Neurology 1999; 52(9)1882–1887, [PUBMED], [INFOTRIEVE], [CSA]
- Ferrari AR, Guerrin R, Gatti G, Alessandri M, Grazia B, Bonanni P, Perucca E. Influence of dosage, age, and co-medication on plasma topimarate concentration in children and adults with severe epilepsy and preliminary observation on correlations with clinical response. Ther Drug Monit 2003; 25(6)700–708, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Reife RA, Pledger G, Doose D, et al. Relationship of steady-state plasma topimarate (Topmax) concentration to clinical efficacy and tolerability. Epilepsia 1995; 36(3)152, [CSA]
- Verhoeven WM, Boermans JA, van der Heijdan FM, Tuinier S. patient's Psychosis following treatment with topiramate. Ned Tijdschr Geneeskd 2003; 147(7)319–320, [CSA]
- Stella F, Caetano D, Cendes F, Guerreiro CA. Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuro-Psiquiatr 2002; 60(2-A)285–287, [CSA]
- Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 1999; 8(4)235–237, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jones MW. Topimarate—safety and tolerability. Can J Neurol Sci 1998; 25: S13–S15, [PUBMED], [INFOTRIEVE], [CSA]
- Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topimarate use. Arch Ophthal-mol 2001; 119: 1210–1211, [CSA]
- Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topimarate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001; 132(1)112–114, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Doan RJ, Clendenning M. Topimarate and hepatotoxicity. Can J Psychiatry 2000; 45(10)937–938, [PUBMED], [INFOTRIEVE], [CSA]